AbbVie 2014 Annual Report Download - page 159

13NOV201221352027
As a result of the Separation, the NEOs held the following Abbott equity awards as of December 31, 2014:
• R. Gonzalez: Options to purchase 89,900 Abbott common shares with exercise prices ranging from $22.39 to
$27.03 per share, which vested on February 17, 2015; performance-vested restricted stock awards covering
19,800 Abbott common shares with a market value of $891,396 as of December 31, 2014, which vested on
February 27, 2015.
• C. Alban: Options to purchase 48,100 Abbott common shares with an exercise price of $27.03 per share, which
vested on February 17, 2015; performance-vested restricted stock awards covering 8,900 Abbott common
shares with a market value of $400,678 as of December 31, 2014, which vested on February 27, 2015.
• L. Schumacher: Options to purchase 265,906 Abbott common shares with exercise prices ranging from $22.39
to $27.03 per share, which vested on February 17, 2015; performance-vested restricted stock awards covering
14,733 Abbott common shares with a market value of $663,280 as of December 31, 2014, which vested on
February 27, 2015.
• W. Chase: Options to purchase 6,533 Abbott common shares with an exercise price of $27.03 per share, which
vested on February 17, 2015; performance-vested restricted stock awards covering 3,633 Abbott common
shares with a market value of $163,558 as of December 31, 2014, which vested on February 27, 2015.
(2) Except as noted, the stock options are fully vested.
(3) The vesting dates of AbbVie unexercisable stock options and unvested restricted stock awards outstanding at
December 31, 2014 are as follows:
R. Gonzalez 35,767 35,767—2/17 19,800 (a)
350,953 175,476—2/14 175,477—2/14 171,813 (b)
281,030 93,677—2/20 93,676—2/20 93,677—2/20 162,960 (c)
M. Severino 74,309 24,770—6/02 24,769—6/02 24,770—6/02 141,625 (d)
C. Alban 16,033 16,033—2/17 8,900 (a)
77,220 38,610—2/14 38,610—2/14 37,800 (b)
81,500 27,167—2/20 27,166—2/20 27,167—2/20 47,260 (c)
35,521 (e)
L. Schumacher 26,600 26,600—2/17 14,733 (a)
97,006 48,503—2/14 48,503—2/14 47,486 (b)
94,140 31,380—2/20 31,380—2/20 31,380—2/20 54,590 (c)
59,202 (e)
W. Chase 6,533 6,533—2/17 3,633 (a)
77,220 38,610—2/14 38,610—2/14 37,800 (b)
92,740 30,914—2/20 30,913—2/20 30,913—2/20 53,770 (c)
44,401 (e)
(a) These are the shares of performance-vested restricted stock that remained outstanding and unvested on
December 31, 2014, from an award made on February 17, 2012. The award has a 5-year term, with no more
than one-third of the original award vesting in any one year upon AbbVie achieving a minimum return on
equity target, measured at the end of the relevant year. In 2014, AbbVie reached its minimum return on
equity target and these shares vested on February 27, 2015.
(b) These are the shares of performance-vested restricted stock that remained outstanding and unvested on
December 31, 2014, from an award made on February 14, 2013. The award has a 5-year term, with no more
than one-third of the original award vesting in any one year upon AbbVie achieving a minimum return on
equity target, measured at the end of the relevant year. In 2014, AbbVie reached its minimum return on
equity target and one-half of the unvested shares vested on February 27, 2015.
2015 Proxy Statement 39
Option Awards Stock Awards
Number of Number of Number of Number of
Unexercised Number of Number of Number of Shares of Shares of Shares of
Shares Option Option Option Restricted Restricted Restricted
Remaining Shares Shares Shares Number of Stock Stock Stock
from Vesting— Vesting— Vesting— Shares of Vesting— Vesting— Vesting—
Original Date Date Date Restricted Date Date Date
Name Grant Vested 2015 Vested 2016 Vested 2017 Stock Vested 2015 Vested 2016 Vested 2017
EXECUTIVE COMPENSATION